COMMUNIQUÉS West-GlobeNewswire

MUHC Foundation President and CEO Marie-Hélène Laramée appointed to Women’s Health Collective Canada Board of Directors
12/08/2026
Laramée’s appointment strengthens Quebec’s voice in the national movement to close gaps in women’s health research, care, and leadership MONTREAL, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The McGill University Health Centre ( [...]
Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026
12/08/2026
PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury, infrastructure, and services company providing institutional access to [...]
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
12/08/2026
Milestone strengthens manufacturing flexibility and supports pivotal study readiness BURLINGTON, Mass, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, [...]
Reflect Scientific Reports More Than $1.4 Million in Freezer-System Sales to Biopharmaceutical Customers
12/08/2026
OREM, Utah, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF) today announced more than $1.4 million in delivered commercial freezer-system sales to six biopharmaceutical companies during the [...]
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
12/08/2026
CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
ADARx Pharmaceuticals Expands Leadership Team with Board and Executive Appointments
12/08/2026
– Ying Huang, Ph.D. appointed to Board of Directors, bringing deep experience spanning executive public biotech leadership, Wall Street and big pharma R&D – – Robert Ackles joins as Chief People Officer, bringing [...]
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/08/2026
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs [...]
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
12/08/2026
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20% Remaining performance [...]
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
12/08/2026
FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with [...]
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
12/08/2026
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established [...]
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
12/08/2026
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and [...]
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to [...]
Novonesis launches Optiva® Triticum to help pasta manufacturers navigate wheat volatility without compromising quality
12/08/2026
COPENHAGEN, Denmark, August 12, 2026 – Novonesis today announced the launch of Optiva® Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, [...]
Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST ® (etripamil) nasal spray Phase 3 registrational trial of etripamil for atrial [...]
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12/08/2026
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 [...]
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12/08/2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases [...]
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
12/08/2026
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing [...]
Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
12/08/2026
Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX [...]
BioPorto A/S to host an investor webcast on the results for the first half of 2026
12/08/2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO [...]

Pages